Clinical Parkinsonism Related Disorders最新文献

{"title":"Orthostatic hypotension and subjective symptomatic orthostasis in Parkinson’s disease: Associations and correlations","authors":"Jillian M. Heisler ,&nbsp;Jon Toledo-Atucha ,&nbsp;Chih-Chun Lin ,&nbsp;Harsh N. Patel ,&nbsp;William G. Ondo","doi":"10.1016/j.prdoa.2024.100262","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100262","url":null,"abstract":"<div><h3>Background</h3><p>Both measured orthostatic hypotension and symptomatic orthostasis are common in PD but their relationship is unclear.</p></div><div><h3>Objective</h3><p>We aim to determine clinical predictors of both measured orthostatic hypotension and reported symptomatic orthostasis in PD, including the impact of “on”/“off” status and seasons, and to determine the correlation between measured OH and subjective orthostasis.</p></div><div><h3>Methods</h3><p>We analyzed BP readings, demographic and disease state predictors for both 1. Measured blood pressure OH criteria and 2. The subjective report of orthostatic symptoms, using logistic regression analyses from an initial “on” motor state clinical visit in all PD patient visits. We then correlated subjective orthostasis symptoms with BP measurements. We also compared intra-subject BP measures in PD patients seen in both “on” and “off” states, and when seen “on” in both summer and winter.</p></div><div><h3>Results</h3><p>723 consecutive visits over 2 years identified 250 unique PD individuals. Subjective orthostasis was reported by 44 % and “on” measured OH (&gt;20 drop in SBP or 10 DBP upon standing) was seen in 30 %. Measured OH did not significantly correlate with any assessed clinical feature or specific medicine. Subjective orthostasis correlated most with older age, dementia, and L-dopa use. Subjective orthostasis correlated equally with absolute lower measured standing SBP and the drop in SBP from sitting to standing. Compared to the “off” state, “on” state showed lower sitting and standing SBP, more than DBP, but no significant change in BP drop upon standing. Seasons did not impact measured BP.</p></div><div><h3>Conclusions</h3><p>Both OH and symptomatic orthostasis are common. Dopaminergic medications did not cause traditionally defined OH but lowered all SBP (sitting and standing) and thus reduced pulse pressure, possibly by increasing arteriole compliance simply by reducing motor tone, as this BP-lowering effect may be specific to Parkinsonism.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100262"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000331/pdfft?md5=42edf063500ffdb6a0c88fae7251bed3&pid=1-s2.0-S2590112524000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141605780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson’s disease experiencing OFF episodes: A modified Delphi panel","authors":"Stuart H. Isaacson ,&nbsp;Richard Dewey ,&nbsp;Robert A. Hauser ,&nbsp;Daniel Kremens ,&nbsp;Rajeev Kumar ,&nbsp;Mark Lew ,&nbsp;William Ondo ,&nbsp;Fernando Pagan ,&nbsp;Kelly E. Lyons ,&nbsp;Rajesh Pahwa","doi":"10.1016/j.prdoa.2024.100264","DOIUrl":"10.1016/j.prdoa.2024.100264","url":null,"abstract":"<div><h3>Introduction</h3><p>In the United States (US), prophylactic treatment with the antiemetic trimethobenzamide has been used before initiating apomorphine therapy. However, US trimethobenzamide stores have been depleted, leaving uncertainty regarding whether antiemetic pretreatment is needed.</p></div><div><h3>Methods</h3><p>This modified Delphi panel aimed to inform circumstances when apomorphine is initiated without antiemetic pretreatment. During Round 1, a panel of 9 US movement disorder specialists rated the appropriateness of prescribing apomorphine therapy with and without antiemetic pretreatment across 192 patient scenarios and were able to review their scores in relation to other scores. During the Round 2, consensus was defined for each scenario as either strong (&gt;75 % agreement) or moderate (66 % agreement).</p></div><div><h3>Results</h3><p>There was strong consensus on 118 of 192 scenario’s (97 as appropriate and 21 as inappropriate), moderate consensus on 29 scenarios, some agreement on 32 scenarios, and lack of agreement on 13 scenarios. In the absence of an antiemetic, there was strong consensus that titration schedules should be flexible and based on dose response. However, the group only reached moderate consensus on the speed of titration, highlighting the need for more systematic information on this area. In the presence of an antiemetic, panelists considered usual initial dosing and flexible titration to be appropriate in most scenarios except for when the patient is already experiencing dopaminergic adverse events.</p></div><div><h3>Conclusions</h3><p>Experts generally reached consensus that apomorphine can usually be prescribed without antiemetic pretreatment. Recommendations described here reflect the areas of greatest agreement among a panel of experts based on current available evidence.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100264"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000355/pdfft?md5=6ba220423b62c813059f60b2494d160c&pid=1-s2.0-S2590112524000355-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141716095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Creutzfeldt-Jakob disease at Siriraj Hospital, Thailand: Case series and literature review","authors":"Chaisak Dumrikarnlert ,&nbsp;Nuttapong Kanokkawinwong ,&nbsp;Chatchawan Rattanabannakit ,&nbsp;Vorapun Senanarong","doi":"10.1016/j.prdoa.2024.100281","DOIUrl":"10.1016/j.prdoa.2024.100281","url":null,"abstract":"<div><h3>Introduction</h3><div>Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive, fatal, neurodegenerative disease classified as prion diseases. There are many subtypes of this disease, but information about clinical presentation and investigation findings in Thailand is scarce.</div></div><div><h3>Objective</h3><div>To describe the clinical presentation, radiological and electroencephalographic characteristics of CJD encountered at Siriraj hospital in the past 10 years (between January 1, 2006 and December 31, 2015).</div></div><div><h3>Materials and Methods</h3><div>This was descriptive epidemiological data (retrospective, observational study). Patients with rapidly progressive dementia who met the diagnostic criteria for sporadic CJD (sCJD) and variant CJD (vCJD) were included. All were investigated in detail to find any other possible treatable cause including brain magnetic resonance imaging (MRI), electroencephalography (EEG), and cerebrospinal fluid (CSF) analysis.</div></div><div><h3>Results</h3><div>Of the 18 cases, they were classified as sCJD 15 cases and possible vCJD 3 cases. The mean age of the patients was 60.72 years (range: 24‐77) and 10 patients were male. The main clinical manifestations were cognitive disturbance (100 %) and myoclonus (14 out of 18 cases, 77 %). Brain imaging abnormalities were observed in 17 patients: Hyperintensities in diffusion weight imaging (DWI) in the cortical regions (temporal, parietal, and occipital) were observed in 94 % of the patients. Classical EEG of periodic epileptiform discharges were observed in 83.33 % of patients.</div></div><div><h3>Conclusions</h3><div>CJD is a rare but fatal disease that needs to be considered in the patient with cognitive, neuropsychiatric, and movement disorders. Findings of specific abnormalities on brain imaging and/or EEG can support the diagnosis in suspicious cases.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100281"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meaning in life and Parkinson’s disease in the UK Biobank","authors":"Angelina R. Sutin ,&nbsp;Martina Luchetti ,&nbsp;Yannick Stephan ,&nbsp;Antonio Terracciano","doi":"10.1016/j.prdoa.2023.100231","DOIUrl":"https://doi.org/10.1016/j.prdoa.2023.100231","url":null,"abstract":"<div><h3>Introduction</h3><p>Meaning in life is an aspect of eudaimonic well-being associated with lower dementia risk. This research examines whether this protective association extends to Parkinson’s disease (PD).</p></div><div><h3>Methods</h3><p>Participants (<em>N</em> = 153,569) from the UK Biobank reported on their meaning in life. Cases of PD were identified through health records.</p></div><div><h3>Results</h3><p>Meaning in life was associated with a 50 % lower likelihood of prevalent PD (OR = 0.68, 95 % CI = 0.59–0.78). Over the 5-year follow-up, meaning was associated with a 35 % lower risk of incident PD (HR = 0.74, 95 % CI = 0.65–0.83), an association robust to sociodemographic characteristics, depression, history of seeking mental health care, smoking, physical activity, and genetic risk and not moderated by age, sex, education, deprivation, or genetic risk.</p></div><div><h3>Conclusions</h3><p>Meaning in life is associated with lower risk of incident PD, an association independent of other major risk factors and generalizable across sociodemographic groups. Meaning is a promising target of intervention for common neurodegenerative diseases.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259011252300049X/pdfft?md5=13f5541a2e83d4991c76267b5ffb5daa&pid=1-s2.0-S259011252300049X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139100978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of zonisamide on sleep and rapid eye movement sleep behavioral disorders in patients with Parkinson’s disease: A randomized control trial","authors":"Hiroshi Kataoka ,&nbsp;Masahiro Isogawa ,&nbsp;Hitoki Nanaura ,&nbsp;Hiroyuki Kurakami ,&nbsp;Miyoko Hasebe ,&nbsp;Kaoru Kinugawa ,&nbsp;Takao Kiriyama ,&nbsp;Tesseki Izumi ,&nbsp;Masato Kasahara ,&nbsp;Kazuma Sugie","doi":"10.1016/j.prdoa.2024.100285","DOIUrl":"10.1016/j.prdoa.2024.100285","url":null,"abstract":"<div><h3>Introduction</h3><div>Zonisamide is a medication developed in Japan that is effective for motor symptoms and wearing off in Parkinson’s disease (PD). Zonisamide has properties that may improve sleep disorders. The aim of this study is to verify the safety and efficacy of zonisamide for sleep disorders and rapid eye movement (REM) sleep behavioral disorders (RBD) using a mobile two-channel electroencephalography /electrooculography recording system in patients with PD.</div></div><div><h3>Methods</h3><div>The present study is a single-blind randomized placebo-controlled trial.<!--> <!-->The subjects in the treatment group took zonisamide (25 mg per day) before bedtime. The primary outcome was sleep efficiency. The secondary endpoints were assessed as followed; objective outcomes of TST<em>,</em> WASO, SOL, REM sleep/non-REM sleep ratio, deep sleep (N3) time, ratio of RWA to total REM sleep epochs, and subjective outcomes of the PDSS-2, Pittsburgh sleep questionnaire, and RBDSQ.</div></div><div><h3>Results</h3><div>Between the zonisamide and placebo groups, no significant differences were found in the primary outcome and secondary outcomes.</div></div><div><h3>Conclusions</h3><div>The objective and subjective sleep metrics in this clinical trial did not significantly demonstrate zonisamide efficacy for sleep disorder in patients with PD. Although not significant,<!--> <!-->improvement in WASO and SOL was observed when zonisamide was compared with the placebo.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100285"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Kazakh version of the movement disorder Society-Unified Parkinson's disease rating scale","authors":"Saltanat Abdraimova ,&nbsp;Zhanybek Myrzayev ,&nbsp;Altynay Karimova ,&nbsp;Altynay Talgatkyzy ,&nbsp;Talgat Khaibullin ,&nbsp;Gulnaz Kaishibayeva ,&nbsp;Sandugash Elubaeva ,&nbsp;Karlygash Esembekova ,&nbsp;Dongrak Choi ,&nbsp;Pablo Martinez-Martin ,&nbsp;Christopher G. Goetz ,&nbsp;Glenn T. Stebbins ,&nbsp;Sheng Luo ,&nbsp;Chingiz Shashkin ,&nbsp;Nazira Zharkinbekova ,&nbsp;Rauan Kaiyrzhanov","doi":"10.1016/j.prdoa.2024.100232","DOIUrl":"10.1016/j.prdoa.2024.100232","url":null,"abstract":"<div><h3>Background and Purpose</h3><p>The International Movement Disorder Society revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) is widely used in the assessment of the severity of Parkinson’s disease (PD). This study aimed to validate the Kazakh version of the MDS-UPDRS, explore its dimensionality, and compare it to the original English version.</p></div><div><h3>Methods</h3><p>The validation was conducted in three phases: first, the English version of the MDS-UPDRS was translated into Kazakh and thereafter back-translated into English by two independent teams; second, the Kazakh version underwent a cognitive pretesting; third, the Kazakh version was tested in 360 native Kazakh-speaking PD patients. Both confirmatory and exploratory factor analyses were performed to validate the scale. We calculated the comparative fit index (CFI) for confirmatory factor analysis and used unweighted least squares for exploratory factor analysis.</p></div><div><h3>Results</h3><p>The CFI was higher than 0.90 for all parts of the scale, thereby meeting the pre-set threshold for the official designation of a validated translation. Exploratory factor analysis also showed that the Kazakh MDS-UPDRS has the analogous factors structure in each part as the English version.</p></div><div><h3>Conclusions</h3><p>The Kazakh MDS-UPDRS had a consistent overall structure as the English MDS-UPDRS, and it was designated as the official Kazakh MDS-UPDRS, which can reliably be used in the Kazakh-speaking populations. Presently, Kazakhstan stands as the sole country in both Central Asia and Transcaucasia with an MDS-approved translated version of the MDS-UPDRS. We expect that other Central Asian and Transcaucasian countries will embark on the MDS Translation Program for MDS-UPDRS in the near future.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100232"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259011252400001X/pdfft?md5=7507318bbf0ae4d7de353871d67c1485&pid=1-s2.0-S259011252400001X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139396136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valosin-containing-protein pathogenic variant p.R487H in Parkinson’s disease","authors":"Capucine Piat,&nbsp;Owen A. Ross,&nbsp;Wolfdieter Springer,&nbsp;Eduardo E. Benarroch,&nbsp;J. Layne Moore,&nbsp;Emily Lauer,&nbsp;Zhiyv Niu,&nbsp;Rodolfo Savica","doi":"10.1016/j.prdoa.2024.100236","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100236","url":null,"abstract":"<div><p>We describe a 66-year-old woman with Parkinson’s disease, carrying a known pathogenic missense variant in the Valosin-containing-protein (<em>VCP</em>) gene. She responded excellently to L-dopa, had no cognitive or motoneuronal dysfunction. Laboratory analyses and MRI were unremarkable. Genetic testing revealed a heterozygous variant in <em>VCP</em>(NM_007126.5), chr9 (GRCh3 7):g.35060820C &gt; T, c.1460G &gt; A p.Arg487His (p.R487H).</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100236"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000057/pdfft?md5=e55fd004326e5eadac7a281cd165485b&pid=1-s2.0-S2590112524000057-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139549345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucuna beans administered through hydrogen-infused superheated steam in advanced Parkinson's disease","authors":"Ryuji Neshige,&nbsp;Shuichiro Neshige","doi":"10.1016/j.prdoa.2024.100252","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100252","url":null,"abstract":"<div><p>This retrospective review on patients with Parkinson's disease, focusing on using mucuna beans (MB), its dosing, and administration methods. Two hundred patients taking 1–3 g of MP dissolved in hot water daily orally. Besides, MB administration via enema may be viable, especially when oral L-dopa efficacy is insufficient.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000239/pdfft?md5=97b83fa446a45b1c199dc1390659ce2b&pid=1-s2.0-S2590112524000239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140551590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive supranuclear palsy phenotype as an atypical clinical presentation of Creutzfeldt-Jakob disease: A case report and review of the literature","authors":"Matteo Costanzo ,&nbsp;Flavia Aiello ,&nbsp;Anna Poleggi ,&nbsp;Pietro Li Voti ,&nbsp;Giovanni Fabbrini ,&nbsp;Daniele Belvisi","doi":"10.1016/j.prdoa.2024.100247","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100247","url":null,"abstract":"<div><p>Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive neurodegenerative disorder, characterized by the accumulation of abnormal prion proteins in the brain. While CJD has some typical clinical features, its presentation can be quite heterogeneous, particularly in the early stages of the disease, posing challenges in diagnosis. Atypical manifestations of CJD can mimic various neurodegenerative disorders, including atypical parkinsonisms. In this case report, we present an 81-year-old man who exhibited an atypical clinical presentation of sporadic CJD, initially resembling progressive supranuclear palsy (PSP). The patient presented with symmetric parkinsonism, postural instability, and ocular motor dysfunction, accompanied by rapid clinical deterioration. Alongside the case report, we also provide a review of the literature on atypical presentations of CJD as PSP, highlighting the importance of recognizing these manifestations in clinical practice.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100247"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000161/pdfft?md5=2accb256acc98b4f2c4ae1f5e4c832a5&pid=1-s2.0-S2590112524000161-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential role of chronic pain and the polytrauma clinical triad in predicting prodromal PD: A cross-sectional study of U.S. Veterans","authors":"Lee E. Neilson ,&nbsp;Nadir M. Balba ,&nbsp;Jonathan E. Elliott ,&nbsp;Gregory D. Scott ,&nbsp;Scott D. Mist ,&nbsp;Matthew P. Butler ,&nbsp;Mary M. Heinricher ,&nbsp;Miranda M. Lim","doi":"10.1016/j.prdoa.2024.100253","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100253","url":null,"abstract":"<div><h3>Introduction</h3><p>The research criteria for prodromal Parkinson disease (pPD) depends on prospectively validated clinical inputs with large effect sizes and/or high prevalence. Neither traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), nor chronic pain are currently included in the calculator, despite recent evidence of association with pPD. These conditions are widely prevalent, co-occurring, and already known to confer risk of REM behavior disorder (RBD) and PD. Few studies have examined PD risk in the context of TBI and PTSD; none have examined chronic pain. This study aimed to measure the risk of pPD caused by TBI, PTSD, and chronic pain.</p></div><div><h3>Methods</h3><p>216 US Veterans were enrolled who had self-reported recurrent or persistent pain for at least three months. Of these, 44 met criteria for PTSD, 39 for TBI, and 41 for all three conditions. Several pain, sleep, affective, and trauma questionnaires were administered. Participants’ history of RBD was determined via self-report, with a subset undergoing confirmatory video polysomnography.</p></div><div><h3>Results</h3><p>A greater proportion of Veterans with chronic pain met criteria for RBD (36 % vs. 10 %) and pPD (18.0 % vs. 8.3 %) compared to controls. Proportions were increased in RBD (70 %) and pPD (27 %) when chronic pain co-occurred with TBI and PTSD. Partial effects were seen with just TBI or PTSD alone. When analyzed as continuous variables, polytrauma symptom severity correlated with pPD probability (r = 0.28, <em>P</em> = 0.03).</p></div><div><h3>Conclusion</h3><p>These data demonstrate the potential utility of chronic pain, TBI, and PTSD in the prediction of pPD, and the importance of trauma-related factors in the pathogenesis of PD.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100253"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000240/pdfft?md5=1782dc09624054d86644af86f9ee1983&pid=1-s2.0-S2590112524000240-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}